CD8A and neoplasm: Similarly, an ovalbumin-specific mRNA vaccine administered with a TLR 7/8 agonist also remarkably improved the expansion of ovalbumin-specific CD8+ T cells and their infiltration into ovalbumin-expressing murine lymphoma and prostate cancer, resulting in significant suppression of tumor growth [181].